Draft:Atai Life Sciences
| Submission declined on 5 July 2021 by CNMall41 (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 20 June 2021 by KylieTastic (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by KylieTastic 3 years ago.
| |
Comment: There are a lot of references on funding but I do not see anything in a search that meets WP:ORGCRIT. In addition, this draft needs to be written more like an encyclopedia page instead of a brochure for the company. Wording such as this ("Atai incorporates a model of developing some assets in house, its primarily employing a “buy and build” strategy where it acquires controlling stakes in early-stage companies") is purely promotion and looks like it was written by someone from the company itself. CNMall41 (talk) 00:38, 5 July 2021 (UTC)
 | |
| NASDAQ: ATAI | |
| Company type | Public |
| Industry | Healthcare |
| Founded | 2018 |
| Headquarters | Berlin, Germany |
Key people | Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao |
| Website | atai Life Sciences |
Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages alternative treatments for mental health disorders. Founded in 2018 and headquartered in Berlin, it has additional offices in New York and London. The company uses a decentralised, technology and data-driven platform model working with various psychedelic compounds such as Psilocybin, R-ketamine and Ibogaine to treat mental health disorders such as depression, anxiety, PTSD and addiction.
History
[edit]The company was founded in 2018 by Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange[1].
Atai incorporates a model of developing some assets in house, its primarily employing a “buy and build” strategy where it acquires controlling stakes in early-stage companies. Thus far company has acquired 3 organisations, their most recent acquisition was Psyber on Apr 7, 2021.[2] These operate as subsidiaries with a shared operational backbone. The first of atai’s psychedelic programs was embodied in Compass Pathways (NASDAQ: CMPS), which conducted an IPO in September of 2020 was valued at over $1.3B as of November 2020.[3]
References
[edit]- ^ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 2021-06-24.
{{cite web}}: CS1 maint: url-status (link) - ^ Shead, Sam (9 April 2021). "Peter Thiel-backed firm takes majority stake in a brain computer interface start-up". CNBC. Retrieved 2021-06-19.
{{cite web}}: CS1 maint: url-status (link) - ^ Woolley, Suzanne (18 September 2020). "'Magic Mushroom' Company Goes Mainstream, Jumps 71% Post-IPO". www.bloomberg.com. Retrieved 2021-06-19.
{{cite web}}: CS1 maint: url-status (link)